Payment overview · 2025
General Payments
$585.06
9 reported records · 6 companies
Healthcare provider profile · identity verified
Sabahat Farooq, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BENSALEM, PA · NPI 1104866441
Verified facts
What the public records show
CMS Open Payments records show Sabahat Farooq, M.D. received $585.06 in general payments during 2025 across 9 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $164.00 | 28.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.99 | 21.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.92 | 21.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $119.70 | 20.5% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $27.41 | 4.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.04 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $585.06 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $164.00 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $124.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1136 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 724 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 628 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 561 | 83 |
| Eliquis | Apixaban | 530 | 68 |
| Furosemide | Furosemide | 528 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 493 | 63 |
| Gabapentin | Gabapentin | 408 | 62 |
| Famotidine | Famotidine | 360 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 352 | 43 |
| Trazodone Hcl | Trazodone Hcl | 324 | 48 |
| Losartan Potassium | Losartan Potassium | 317 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 312 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 305 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 301 | 30 |
| Mirtazapine | Mirtazapine | 293 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 292 | 26 |
| Sertraline Hcl | Sertraline Hcl | 262 | 26 |
| Carvedilol | Carvedilol | 255 | 40 |
| Metformin Hcl | Metformin Hcl | 254 | 39 |
| Donepezil Hcl | Donepezil Hcl | 251 | 26 |
| Levetiracetam | Levetiracetam | 248 | 34 |
| Lisinopril | Lisinopril | 245 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 231 | 25 |
| Risperidone | Risperidone | 212 | 14 |
| Potassium Chloride | Potassium Chloride | 189 | 25 |
| Xarelto | Rivaroxaban | 166 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 161 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 150 | 21 |
| Memantine Hcl | Memantine Hcl | 147 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 140 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 139 | 20 |
| Omeprazole | Omeprazole | 133 | 26 |
| Divalproex Sodium | Divalproex Sodium | 127 | 17 |
| Tramadol Hcl | Tramadol Hcl | 125 | 23 |
| Latanoprost | Latanoprost | 118 | 22 |
| Montelukast Sodium | Montelukast Sodium | 118 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 104 | suppressed |
| Bumetanide | Bumetanide | 100 | 15 |
| Warfarin Sodium | Warfarin Sodium | 100 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 12 |
| Baclofen | Baclofen | 95 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 94 | 12 |
| Buspirone Hcl | Buspirone Hcl | 93 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 91 | 11 |
| Tradjenta | Linagliptin | 91 | suppressed |
| Simvastatin | Simvastatin | 90 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 23 |
| Midodrine Hcl | Midodrine Hcl | 88 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 11 |
| Allopurinol | Allopurinol | 82 | suppressed |
| Finasteride | Finasteride | 82 | 13 |
| Olanzapine | Olanzapine | 75 | 12 |
| Atenolol | Atenolol | 74 | suppressed |
| Entresto | Sacubitril/Valsartan | 74 | 14 |
| Nifedipine Er | Nifedipine | 70 | 13 |
| Lacosamide | Lacosamide | 64 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 20 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 62 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 60 | 17 |
| Sevelamer Carbonate | Sevelamer Carbonate | 60 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 58 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | suppressed |
| Glipizide | Glipizide | 56 | 12 |
| Jardiance | Empagliflozin | 56 | suppressed |
| Aripiprazole | Aripiprazole | 55 | suppressed |
| Clonazepam | Clonazepam | 55 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 15 |
| Ezetimibe | Ezetimibe | 51 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 50 | suppressed |
| Nystatin | Nystatin | 50 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 27 |
| Novolog Flexpen | Insulin Aspart | 48 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 46 | 13 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Digoxin | Digoxin | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 26 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 44 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Cefadroxil | Cefadroxil | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 22 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Nateglinide | Nateglinide | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Amantadine | Amantadine Hcl | 34 | suppressed |
| Lidocaine | Lidocaine | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 33 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | 12 |
| Humalog | Insulin Lispro | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Nyamyc | Nystatin | 32 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Nystop | Nystatin | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 11 |
| Prednisolone Acetate | Prednisolone Acetate | 26 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | 14 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | 17 |
| Torsemide | Torsemide | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 20 | suppressed |
| Auryxia | Ferric Citrate | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 19 | 13 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Prednisone | Prednisone | 18 | 11 |
| Ramipril | Ramipril | 18 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Alogliptin | Alogliptin Benzoate | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 12 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Mesalamine | Mesalamine | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fluorometholone | Fluorometholone | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Acetazolamide Er | Acetazolamide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 13 | suppressed |
| Secuado | Asenapine | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $585.06 · 9 records | SANOFI-AVENTIS U.S. LLC | BREZTRI, INSPIRE, KISUNLA, Nayzilam, REXULTI, TZIELD | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error